Scott Gottlieb, M.D., a practicing physician, has served in various capacities at the Food and Drug Administration, including senior adviser for medical technology; director of medical policy development; and, most recently, deputy commissioner for medical and scientific affairs. Dr. Gottlieb has also served as a senior policy adviser at the Centers for Medicare & Medicaid Services.
Click here to read Scott’s Medical Innovation blog.
The Obama Administration’s seemingly imminent decision to give small businesses at least one more year to conform their health insurance plans to new federal rules is a wise if not predictable gesture. But it doesn’t come without costs. Insurance premiums will rise in 2015 to reflect the price of this latest revision.
During this half-day symposium, panelists will consider the opinions of policymakers, health care providers, patients, and other stakeholders in determining how new payment systems can foster patient-centered cancer care, and how informed and empowered patients can be an active part of the resulting payment models.
The decision by the Food and Drug Administration to revamp food labels, to improve disclosure of added sugars and serving sizes, is an important step by an agency that has been singularly effective in recent years at improving the information consumers get about the foods they eat.
In a landmark study of a new cardiovascular device unveiled last month, patients received anesthetics, had a large-bore catheter inserted through a cut into one of their major arteries, and had dye injected into their bloodstream. Their surgeons worked on them for about an hour, with unnecessary pokes and prods, while a monitor displayed the false progress using radioactive fluoroscopy.
There’s been a lot of discussion about whether the risk adjustment tools embedded in ObamaCare amount to a bailout for the insurance companies, or are a reasonable feature of the law. There’s been far less information about how much money the insurers stand to gain from these measures, to offset their expected losses.